Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,758.00
Bid: 1,758.00
Ask: 1,758.50
Change: 2.00 (0.11%)
Spread: 0.50 (0.028%)
Open: 1,743.50
High: 1,759.00
Low: 1,740.50
Prev. Close: 1,756.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: UK Gains Held Back By Miners

Thu, 21st Aug 2014 16:29

LONDON (Alliance News) - UK stocks made gains on Thursday as equity markets across Europe and the US also made strong gains, but the FTSE 100 was held back by mining stocks which were hit by concerns about growth in China.

In the US, the DJIA moved back above 17,000 points, while the S&P 500 hit a new record intraday high, after strong economic data was released. In particular, the US manufacturing PMI came in at 58, up from 55.8 in June and well above economists' expectations for 55.7. It was the highest reading since April 2010.

After the European market close, the DJIA was up 0.4%, the S&P 500 up 0.3%, although the Nasdaq Composite was flat.

European equity markets posted even stronger gains, with the CAC 40 ending up 1.2% and the DAX up 0.9%, despite mixed PMI data.

The eurozone composite PMI slipped to 52.8 in August, from 53.8 in July, missing expectations of 53.4, and the services PMI dropped to 53.5, from 54.2 in July. In Germany, the region's biggest economy, output slowed fractionally. The manufacturing sector PMI came in at 52.0, down from 52.4, but beating expectations of 51.8, while the service sector print was 56.4, down from 56.7, also beating expectations of 55.5.

In the context of the gains in Europe, the London market underperformed as its high number of mining sector constituents weighed. The FTSE 100 ended up 0.3% at 6,777.66, while the FTSE 250 finished up 0.6% at 15,838.57 and the AIM All Share index ended down 0.1% at 763.96.

Mining stocks fell after the Chinese manufacturing PMI slipped to a three month low at 50.3, down from 51.7 in July and missing the market consensus of 51.5. The FTSE 350 mining sector index ended the day down 0.6% with Fresnillo down 3.6%, Randgold Resources down 1.9% and Anglo American down 1.3%.

In the FTSE 250, miner Kazakhmys was the biggest faller, ending down 5.6%. Its pretax loss narrowed in the first-half due to lower write-offs and impairment charges and as its cost cutting programme and efficiency improvements offset lower metals prices and boosted margins. However, revenue fell as it reduced output at several higher cost, lower grade operations as part of its restructuring programme.

Pharmaceuticals led the gainers on the FTSE 100.

AstraZeneca, up 3%, ended the day as the blue-chip index's biggest gainer after it said it has partnered with Illumina to develop a gene-sequencing platform for companion diagnostic tests, applicable across AstraZeneca's oncology portfolio.

The company said Illumina's technology allows gene sequencing that is faster and cheaper than traditional methods, and will be used to screen a panel of several gene sequences, scanning for possible genetic variants, rather than specified mutations from a single tumour sample. This information can then be used to help predict which patients will respond to which treatments.

GlaxoSmithKline ended the day 1.2% higher after the company said late Wednesday that the US Food and Drug Administration has approved its Arnuity Ellipta treatment for asthma in patients aged 12 years and older. It was approved for 100 microgram and 200 microgram doses, and is administered daily via the Ellipta dry powder inhaler, which is also used for a range of other respiratory medicines in Glaxo's portfolio.

The pound dropped Thursday after UK retail sales grew 2.6% on the year in July, down from 3.4% annual growth in June and below economists' forecasts for 3% growth. Sales were up just 0.1% on the month in July, down from 0.2% growth in June and missing the consensus of 0.4% growth.

"There had been some hope that the weakness seen in May and June was a temporary blip for UK consumers but the weakness is persisting into July with only 0.1% growth in the month. Employment is rising but stagnating wages against a backdrop of modest inflation means confidence in future spending ability is being hampered by a short-term squeeze in the cost of living," said Jasper Lawler, an analyst at CMC Markets.

Sterling initially fell sharply in reaction to the news, but recovered throughout the day and was trading at USD1.6590 when the equity markets closed.

Friday's economic calendar is dominated by the Jackson Hole Symposium and speeches by Federal Reserve chief Janet Yellen and European Central Bank President Mario Dragi at 1500 BST and 1930 BST, respectively.

In the corporate calendar, FTSE 250-listed HellermannTyton Group will release interim results.

By Neil Thakrar; neilthakrar@alliancenews.com

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
21 May 2024 11:23

AstraZeneca aims for $80 bln in total revenue by 2030

Sees $80 bln in 2030 revenue by 2030

*

Read more
21 May 2024 08:49

GSK's depemokimab asthma treatment meets endpoints in latest trials

(Alliance News) - GSK PLC on Tuesday announced positive results from trials of depemokimab, an "ultra-long-acting biologic" that could simplify treatment options for patients with severe asthma.

Read more
21 May 2024 07:21

GSK reports promising results from asthma treatment trials

(Sharecast News) - GSK announced promising results from phase three clinical trials evaluating the efficacy and safety of depemokimab in treating severe asthma with type 2 inflammation on Tuesday.

Read more
20 May 2024 16:11

IN BRIEF: GSK executive buys GBP20,026 worth shares

GSK PLC - London-based pharmaceuticals firm - Senior Vice President, Global Communications & Chief Executive Office, Sally Jackson, buys 1,120 shares at 1,788 pence each. Worth total GBP20,026.

Read more
17 May 2024 17:38

London's FTSE nudges lower for week after record run

Haleon falls after GSK offloads remaining stake

*

Read more
17 May 2024 15:52

London close: Stocks recoup some earlier losses

(Sharecast News) - London stocks remained in negative territory by Friday's close, although they managed to recoup some of the losses seen earlier in the session as Wall Street opened with positive momentum.

Read more
17 May 2024 11:52

LONDON MARKET MIDDAY: FTSE 100 slides; Eurozone inflation steady

(Alliance News) - Stock prices in London were lacklustre at midday on Friday, as investors eye the trajectory of interest rates across the globe.

Read more
17 May 2024 09:03

TOP NEWS: GSK sells remaining Haleon stake for GBP1.25 billion

(Alliance News) - GSK PLC on Friday said it has sold its remaining shares in Haleon PLC, marking a total exit from its consumer healthcare spin-off.

Read more
17 May 2024 08:56

LONDON MARKET OPEN: FTSE 100 lacklustre as Wall Street rally ends

(Alliance News) - Stock prices in London opened lower on Friday, after Thursday saw Wall Street's rally end in a record breaking session.

Read more
17 May 2024 08:39

GSK raises $1.5 bln from sale of remaining Haleon stake

May 17 (Reuters) - British drugmaker GSK has raised 1.25 billion pounds ($1.52 billion) from a sale of its remaining stake in consumer healthcare company Haleon to institutional investors.

Read more
17 May 2024 07:42

LONDON BRIEFING: Land Securities ups dividend; GSK sells Haleon stake

(Alliance News) - Stocks in London are called to open lower, as investors wait for an inflation reading from the eurozone later this morning.

Read more
17 May 2024 07:29

GSK raises £1.25bn from sale of remaining Haleon stake

(Sharecast News) - GSK said on Friday that it has sold its remaining 4.2% stake in consumer health business Haleon, which it spun off in July 2022.

Read more
16 May 2024 17:33

FTSE 100 ends lower on disappointing corporate updates, BT Group soars

BT Group up after CEO aims for more than double free cash flow

*

Read more
16 May 2024 17:13

TOP NEWS: GSK to sell remaining holding in spin-off Haleon

(Alliance News) - GSK PLC on Thursday said it intends to sell its remaining stake in Haleon PLC, the consumer healthcare firm it spun out almost two years ago.

Read more
16 May 2024 17:02

GSK to sell entire 4.2% remaining stake in Haleon

(Sharecast News) - GSK said on Thursday that it plans to sell its entire remaining 4.2% stake in Haleon.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.